Literature DB >> 29941432

The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015).

Kevin C Katz1, George R Golding2, Kelly Baekyung Choi2, Linda Pelude2, Kanchana R Amaratunga2, Monica Taljaard2, Stephanie Alexandre2, Jun Chen Collet2, Ian Davis2, Tim Du2, Gerald A Evans2, Charles Frenette2, Denise Gravel2, Susy Hota2, Pamela Kibsey2, Joanne M Langley2, Bonita E Lee2, Camille Lemieux2, Yves Longtin2, Dominik Mertz2, Lorraine Maze Dit Mieusement2, Jessica Minion2, Dorothy L Moore2, Michael R Mulvey2, Susan Richardson2, Michelle Science2, Andrew E Simor2, Paula Stagg2, Kathryn N Suh2, Geoffrey Taylor2, Alice Wong2, Nisha Thampi2.   

Abstract

BACKGROUND: The clinical and molecular epidemiology of health care-associated Clostridium difficile infection in nonepidemic settings across Canada has evolved since the first report of the virulent North American pulsed-field gel electrophoresis type 1 (NAP1) strain more than 15 years ago. The objective of this national, multicentre study was to describe the evolving epidemiology and molecular characteristics of health care-associated C. difficile infection in Canada during a post-NAP1-epidemic period, particularly patient outcomes associated with the NAP1 strain.
METHODS: Adult inpatients with C. difficile infection were prospectively identified, using a standard definition, between 2009 and 2015 through the Canadian Nosocomial Infection Surveillance Program (CNISP), a network of 64 acute care hospitals. Patient demographic characteristics, severity of infection and outcomes were reviewed. Molecular testing was performed on isolates, and strain types were analyzed against outcomes and epidemiologic trends.
RESULTS: Over a 7-year period, 20 623 adult patients admitted to hospital with health care-associated C. difficile infection were reported to CNISP, and microbiological data were available for 2690 patients. From 2009 to 2015, the national rate of health care-associated C. difficile infection decreased from 5.9 to 4.3 per 10 000 patient-days. NAP1 remained the dominant strain type, but infection with this strain has significantly decreased over time, followed by an increasing trend of infection with NAP4 and NAP11 strains. The NAP1 strain was significantly associated with a higher rate of death attributable to C. difficile infection compared with non-NAP1 strains (odds ratio 1.91, 95% confidence interval [CI] 1.29-2.82). Isolates were universally susceptible to metronidazole; one was nonsusceptible to vancomycin. The proportion of NAP1 strains within individual centres predicted their rates of health care-associated C. difficile infection; for every 10% increase in the proportion of NAP1 strains, the rate of health care-associated C. difficile infection increased by 3.3% (95% CI 1.7%-4.9%).
INTERPRETATION: Rates of health care-associated C. difficile infection have decreased across Canada. In nonepidemic settings, NAP4 has emerged as a common strain type, but NAP1, although decreasing, continues to be the predominant circulating strain and remains significantly associated with higher attributable mortality.
© 2018 Joule Inc. or its licensors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29941432      PMCID: PMC6019340          DOI: 10.1503/cmaj.180013

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  20 in total

1.  NAP1 strain type predicts outcomes from Clostridium difficile infection.

Authors:  Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa
Journal:  Clin Infect Dis       Date:  2014-03-05       Impact factor: 9.079

Review 2.  Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile.

Authors:  Christopher R Polage; Jay V Solnick; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

Review 3.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality.

Authors:  Mark Miller; Denise Gravel; Michael Mulvey; Geoffrey Taylor; David Boyd; Andrew Simor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

5.  Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.

Authors:  J Freeman; J Vernon; K Morris; S Nicholson; S Todhunter; C Longshaw; M H Wilcox
Journal:  Clin Microbiol Infect       Date:  2014-10-13       Impact factor: 8.067

6.  Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.

Authors:  T Scardina; L Labuszewski; S M Pacheco; W Adams; P Schreckenberger; S Johnson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03       Impact factor: 3.254

7.  Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting.

Authors:  Jeffrey Cloud; Laura Noddin; Amanda Pressman; Mary Hu; Ciaran Kelly
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05-22       Impact factor: 11.382

8.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.

Authors:  Denise Gravel; Mark Miller; Andrew Simor; Geoffrey Taylor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly; David Boyd; Michael Mulvey
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

Review 9.  New trends in Clostridium difficile virulence and pathogenesis.

Authors:  C Denève; C Janoir; I Poilane; C Fantinato; A Collignon
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

10.  Emergence of an outbreak-associated Clostridium difficile variant with increased virulence.

Authors:  Carlos Quesada-Gómez; Diana López-Ureña; Luis Acuña-Amador; Manuel Villalobos-Zúñiga; Tim Du; Rosemayre Freire; Caterina Guzmán-Verri; María del Mar Gamboa-Coronado; Trevor D Lawley; Edgardo Moreno; Michael R Mulvey; Gerly Anne de Castro Brito; Evelyn Rodríguez-Cavallini; César Rodríguez; Esteban Chaves-Olarte
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

View more
  16 in total

1.  Incidence and economic burden of Clostridioides difficile infection in Ontario: a retrospective population-based study.

Authors:  Jennifer A Pereira; Allison McGeer; Antigona Tomovici; Alex Selmani; Ayman Chit
Journal:  CMAJ Open       Date:  2020-01-30

2.  Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain.

Authors:  T J Carlson; D Blasingame; A J Gonzales-Luna; F Alnezary; K W Garey
Journal:  Anaerobe       Date:  2019-12-19       Impact factor: 3.331

3.  Epidemiology of Clostridium (Clostridioides) difficile Infection in Southeast Asia.

Authors:  Peng An Khun; Thomas V Riley
Journal:  Am J Trop Med Hyg       Date:  2022-08-08       Impact factor: 3.707

4.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

Authors:  Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

5.  Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study.

Authors:  Seth R Shaffer; Zoann Nugent; Andrew Walkty; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein; Harminder Singh
Journal:  CMAJ Open       Date:  2020-11-16

6.  Trends in health care-associated infections in acute care hospitals in Canada: an analysis of repeated point-prevalence surveys.

Authors:  Robyn Mitchell; Geoffrey Taylor; Wallis Rudnick; Stephanie Alexandre; Kathryn Bush; Leslie Forrester; Charles Frenette; Bonny Granfield; Denise Gravel-Tropper; Jennifer Happe; Michael John; Christian Lavallee; Allison McGeer; Dominik Mertz; Linda Pelude; Michelle Science; Andrew Simor; Stephanie Smith; Kathryn N Suh; Joseph Vayalumkal; Alice Wong; Kanchana Amaratunga
Journal:  CMAJ       Date:  2019-09-09       Impact factor: 8.262

7.  Epidemiology of Clostridioides difficile infection in Canada: A six-year review to support vaccine decision-making.

Authors:  Y Xia; M C Tunis; C Frenette; K Katz; K Amaratunga; S Rhodenizer Rose; A House; C Quach
Journal:  Can Commun Dis Rep       Date:  2019-07-04

8.  Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.

Authors:  Elaine Finn; Fredrik L Andersson; Matthew Madin-Warburton
Journal:  BMC Infect Dis       Date:  2021-05-19       Impact factor: 3.090

9.  Mortality review as a tool to assess the contribution of healthcare-associated infections to death: results of a multicentre validity and reproducibility study, 11 European Union countries, 2017 to 2018.

Authors:  Tjallie van der Kooi; Alain Lepape; Pascal Astagneau; Carl Suetens; Mioara Alina Nicolaie; Sabine de Greeff; Ilma Lozoraitiene; Jacek Czepiel; Márta Patyi; Diamantis Plachouras
Journal:  Euro Surveill       Date:  2021-06

Review 10.  Epidemiology of community-acquired and recurrent Clostridioides difficile infection.

Authors:  Yichun Fu; Yuying Luo; Ari M Grinspan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-22       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.